The fallacies of hope: Will we discover new antibiotics to combat pathogenic bacteria in time?

FEMS Microbiology Reviews

Volumn 30, Issue 6, 2006, Pages 841-852

  Vicente, Miguel ^a   Hodgson, John ^b   Massidda, Orietta ^c   Tonjum, Tone ^d   Henriques Normark, Birgitta ^e   Ron, Eliora Z ^f  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b Mutabilis Parc Biocitech   (France)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF OSLO   (Norway)

^e KAROLINSKA INSTITUTE   (Sweden)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antibiotic resistance; Antibiotics; Antimicrobial targets; Drug development; Genomics; Infectious disease

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL PROTEIN; DAPTOMYCIN; FTSZ PROTEIN; LINEZOLID; PROTEIN FTSA; PROTEIN ZIPA; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENOME; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BIOTECHNOLOGY; DRUG USE; FUNCTIONAL GENOMICS; FUNCTIONAL PROTEOMICS; GENETIC ENGINEERING; GENOMICS; GROWTH INHIBITION; HAEMOPHILUS INFLUENZAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOBACTERIUM; NONHUMAN; PATHOGENIC ESCHERICHIA COLI; PHENOTYPE; PLASMID; SOCIOECONOMICS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PHYSIOLOGICAL PHENOMENA; BACTERIAL PHYSIOLOGY; BACTERIAL PROTEINS; CELL DIVISION; DRUG COMPOUNDING; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; GENOME, BACTERIAL; GENOMICS; HUMANS; RNA, BACTERIAL; RNA, MESSENGER; VIRULENCE; WORLD HEALTH;

EID: 33750090037     PISSN: 01686445     EISSN: 15746976     Source Type: Journal    
DOI: 10.1111/j.1574-6976.2006.00038.x     Document Type: Article

References (86)

1. Andersson DI (2003) Persistence of antibiotic resistant bacteria. Curr Opin Microbiol 6: 452-456.
2. Armstrong GL, Conn LA & Pinner RW (1999) Trends in infectious disease mortality in the United States during the 20th century. J Am Med Assoc 281: 61-66.
3. Bardos TJ (1974) Antimetabolites: molecular design and mode of action. Top Curr Chem 52: 63-98.
4. Barrett JF (2005) Can biotech deliver new antibiotics? Curr Opin Microbiol 8: 498-503.
5. Bartlett JG, Breiman RF, Mandell LA & File TM Jr (1998) Community-acquired pneumonia in adults: guidelines for management. The infectious diseases society of America. Clin Infect Dis 26: 811-838.
6. Bernatoniene J & Finn A (2005) Advances in pneumococcal vaccines: advantages for infants and children. Drugs 65: 229-255.
7. Bishai W (2002) The in vivo-in vitro paradox in pneumococcal respiratory tract infections. J Antimicrob Chemother 49: 433-436.
8. Blomberg B, Jureen R, Manji KP et al. (2005) High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-spectrum beta-lactamases in Dar es Salaam, Tanzania. J Clin Microbiol 43: 745-749.
9. Branger C, Zamfir O, Geoffroy S, Laurans G, Arlet G, Thien HV, Gouriou S, Picard B & Denamur E (2005) Genetic background of Escherichia coli and extended-spectrum beta-lactamase type. Emerg Infect Dis 11: 54-61.
10. Bush K (2004) Why it is important to continue antibacterial drug discovery. ASM News 70: 282-287.
11. Camacho AG, Misselwitz R, Behlke J, Ayora S, Welfle K, Meinhart A, Lara B, Saenger W, Welfle H & Alonso JC (2002) In vitro and in vivo stability of the epsilon2zeta2 protein complex of the broad host-range Streptococcus pyogenes pSM19035 addiction system. Biol Chem 383: 1701-1713.
12. Cantón R, Coque TM & Baquero F (2003) Multi-resistant gram-negative bacilli: from epidemics to endemics. Curr Opin Infect Dis 16: 315-325.
13. Courvalin P & Davies J (2003) Antimicrobials. Curr Opin Microbiol 6: 425-529.
14. Dai K, Mukherjee A, Xu Y & Lutkenhaus J (1994) Mutations in ftsZ that confer resistance to SulA affect the interaction of FtsZ with GTP. J Bacteriol 176: 130-136.
15. Davies J (1994) Inactivation of antibiotics and the dissemination of resistance genes. Science 264: 375-382.
16. D'Costa VM, McGrann KM, Hughes DW & Wright GD (2006) Sampling the antibiotic resistome. Science 311: 374-377.
17. Deane SM & Rawlings DE (2004) Plasmid evolution and interaction between the plasmid addiction stability systems of two related broad-host-range IncQ-like plasmids. J Bacteriol 186: 2123-2133.
18. de Boer P, Crossley R & Rothfield L (1992) The essential bacterial cell division protein FtsZ is a GTPase. Nature 359: 254-256.
19. Engelberg-Kulka H, Sat B, Reches M, Amitai S & Hazan R (2004) Bacterial programmed cell death systems as targets for antibiotics. Trends Microbiol 12: 66-71.
20. Farr BM, Salgado CD, Karchmer TB & Sherertz RJ (2001) Can antibiotic-resistant nosocomial infections be controlled? Lancet Infect Dis 1: 38-45.
21. Felmingham D (2004) Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy 50(Suppl 1): 3-10.
22. Felmingham D, Feldman C, Hryniewicz W, Klugman K, Kohno S, Low DE, Mendes C & Rodloff AC (2002) Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect 8(Suppl 2): 12-42.
23. Fields KA & Hackstadt T (2000) Evidence for the secretion of Chlamydia trachomatis CopN by a type III secretion mechanism. Mol Microbiol 38: 1048-1060.
24. Frazão N, Brito-Avô A, Simas C et al. (2005) Effect of the seven-valent conjugate pneumococcal vaccine on carriage and drug resistance of Streptococcus pneumoniae in healthy children attending day-care centers in Lisbon. Pediatr Infect Dis J 24: 243-252.
25. Gerdes K, Christensen KS & Lobner-Olensen A (2005) Prokaryotic toxin-antitoxin stress response loci. Nat Rev Microbiol 3: 371-382.
26. Girardeau JP, Lalioui L, Said AM, De Champs C & Le Bouguenec C (2003) Extended virulence genotype of pathogenic Escherichia coli isolates carrying the afa-8 operon: evidence of similarities between isolates from humans and animals with extraintestinal infections. J Clin Microbiol 41: 218-226.
27. Gophna U, Barlev M, Seijffers R, Oelschlager TA, Hacker J & Ron EZ (2001) Curli fibers mediate internalization of Escherichia coli by eukaryotic cells. Infect Immun 69: 2659-2665.
28. Gophna U, Oelschlaeger TA, Hacker J & Ron EZ (2002) Role of fibronectin in curli-mediated internalization. FEMS Microbiol Lett 212: 55-58.
29. Greenwood D (1981) In vitro veritas? Antimicrobial susceptibility tests and their clinical relevance. J Infect Dis 144: 380-385.
30. Hitchings GH (1971) Folate antagonists as antibacterial and antiprotozoal agents. Ann N Y Acad Sci 186: 444-451.
31. Hoffman LR, D'Argenio DA, MacCoss MJ, Zhang Z, Jones RA & Miller SI (2005) Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436: 1171-1175.
32. Hung DT, Shakhnovich EA, Pierson E & Mekalanso JJ (2005) Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310: 670-674.
33. Jackson LA, Benson P, Neuzil KM, Grandjean M & Marino JL (2005) Burden of community-onset Escherichia coli bacteremia in seniors. J Infect Dis 191: 1523-1529.
34. Jennings LD, Foreman KW, Rush TS III et al. (2004) Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction. Bioorg Med Chem 12: 5115-5131.
35. Jensen RB, Grohmann E, Schwab H, Díaz-Orejas R & Gerdes K (1995) Comparison of ccd of F, parDE of RP4, and parD of R1 using a novel conditional replication control system of plasmid R1. Mol Microbiol 17: 211-220.
36. Johnson JR & Russo TA (2002) Extraintestinal pathogenic Escherichia coli: "the other bad E coli". J Lab Clin Med 139: 155-162.
37. Jones ME, Blosser-Middleton RS, Critchley IA, Karlowsky JA, Thornsberry C & Sahm DF (2003) In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001. Clin Microbiol Infect 9: 590-599.
38. Klein DL (1999) Pneumococcal disease and the role of the conjugate vaccines. Microb Drug Resist 5: 147-157.
39. Kollef MH (2003) The importance of appropriate initial antibiotic therapy for hospital-acquired infections. Am J Med 115: 582-584.
40. Kourbatova EV, Halvosa JS, King MD, Ray SM, White N & Blumberg HM (2005) Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections. Am J Infect Control 33: 385-391.
41. Levy SB & Marshall B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10: S122-S129.
42. Löwe J & Amos LA (1998) Crystal structure of the bacterial cell-division protein FtsZ. Nature 391: 203-206.
43. Macfarlane JT, Colville A, Guion A, Macfarlane RM & Rose DH (1993) Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 341: 511-514.
44. Madden JC, Ruiz N & Caparon M (2001) Cytolysin-mediated translocation (CMT): a functional equivalent of type III secretion in gram-positive bacteria. Cell 104: 143-152.
45. Mahan MJ, Heithoff DM, Sinsheimer RL & Low DA (2000) Assessment bacterial pathogenesis analysis of gene expression in the host. Annu Rev Genet 34: 139-164.
46. Maione D, Margarit I, Rinaudo CD et al. (2005) Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309: 148-150.
47. Martínez JL & Baquero F (2002) Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin Microbiol Rev 15: 647-679.
48. Maslow JN, Lautenbach E, Glaze T, Bilker W & Johnson JR (2004) Colonization with extraintestinal pathogenic Escherichia coli among nursing home residents and its relationship to fluoroquinolone resistance. Antimicrob Agents Chemother 48: 3618-3620.
49. Mattick JS (2005) The functional genomics of noncoding RNA. Science 309: 1527-1528.
50. Medini D, Donati C, Tettelin H, Masignani V & Rappuoli R (2005) The microbial pan-genome. Curr Opin Genet Dev 15: 589-594.
51. Mingorance J, Rueda S, Gómez-Puertas P, Valencia A & Vicente M (2001) Escherichia coli FtsZ polymers contain mostly GTP and have a high nucleotide turnover. Mol Microbiol 41: 83-91.
52. Moir DT, Shaw KJ, Hare RS & Vovis GF (1999) Genomics and antimicrobial drug discovery. Antimicrob Agents Chemother 43: 439-446.
53. Mokady D, Gophna U & Ron EZ (2005) Virulence factors of septicemic Escherichia coli strains. Int J Med Microbiol 295: 455-462.
54. Morens DM, Folkers GK & Fauci AS (2004) The challenge of emerging and re-emerging infectious diseases. Nature 430: 242-249.
55. Mukherjee A, Dai K & Lutkenhaus J (1993) Escherichia coli cell division protein FtsZ is a guanine nucleotide binding protein. Proc Natl Acad Sci USA 90: 1053-1057.
56. Murray S (2006) Challenges of tuberculosis control. Can Med Assoc J 174: 33-34.
57. Pandey DP & Gerdes K (2005) Toxin-antitoxin loci are highly abundant in free-living but lost from host-associated prokaryotes. Nucleic Acids Res 33: 966-976.
58. Payne DJ (2004) Antimicrobials - where next? Microbiol today 31: 55-57.
59. Phillips I (2001) Reevaluation of antibiotic breakpoints. Clin Infect Dis 33(Suppl 3): 230-232.
60. Projan SJ (2003) Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6: 427-430.
61. Rawlings DE (1999) Proteic toxin-antitoxin, bacterial plasmid addiction systems and their evolution with special reference to the pas system of pTF-FC2. FEMS Microbiol Lett 176: 269-277.
62. RayChaudhuri D & Park JT (1992) Escherichia coli cell division gene ftsZ encodes a novel GTP-binding protein. Nature 359: 251-254.
63. Riley M, Abe T, Arnaud MB et al. (2006) Escherichia coli K-12: a cooperatively developed annotation snapshot-2005. Nucleic Acids Res 34: 1-9.
64. Romberg L & Mitchison TJ (2004) Rate-limiting guanosine 5′-triphosphate hydrolysis during nucleotide turnover by FtsZ, a prokaryotic tubulin homologue involved in bacterial cell division. Biochemistry 43: 282-288.
65. Ron EZ (2006) Host specificity of Escherichia coli: human and avian pathogens. Curr Opin Microbiol 9: 28-32.
66. Rosamond J & Allsop A (2000) Harnessing the power of the genome in the search for new antibiotics. Science 287: 1973-1976.
67. Rosqvist R, Hakansson S, Forsberg A & Wolf-Watz H (1995) Functional conservation of the secretion and translocation machinery for virulence proteins of yersiniae, salmonellae and shigellae. EMBO J 14: 4187-4195.
68. Rush TS III, Grant JA, Mosyak L & Nicholls A (2005) A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J Med Chem 48: 1489-1495.
69. Sánchez M, Valencia A, Ferrándiz MJ, Sander C & Vicente M (1994) Correlation between the structure and biochemical activities of FtsA, an essential cell division protein of the actin family. EMBO J 13: 4919-4925.
70. Sanders CC (1991) A problem with antimicrobial susceptibility tests. ASM News 57: 187-190.
71. Schrag SJ, McGee L, Whitney CG, Beall B, Craig AS, Choate ME, Jorgensen JH, Facklam RR, Klugman KP & the Active Bacterial Core Surveillance Team (2004) Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob Agents Chemother 48: 3016-3023.
72. Siegman-Igra Y, Fourer B, Orni-Wasserlauf R, Golan Y, Noy A, Schwartz D & Giladi M (2002) Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. Clin Infect Dis 34: 1431-1439.
73. Smith AS & Rawlings DE (1998) Autoregulation of the pTF-FC2 proteic poison-antidote plasmid addiction system (pas) is essential for plasmid stabilization. J Bacteriol 180: 5463-5465.
74. Stevenson KB, Searle K, Stoddard GJ & Samore M (2005) Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in rural communities, western United States. Emerg Infect Dis 11: 895-903.
75. Tettelin H, Masignani V, Cieslewicz MJ et al. (2005) Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". Proc Natl Acad Sci USA 102: 13950-13955 (Erratum in: 102:16530).
76. The WHO Western Pacific Gonococcal Antimicrobial Surveillance Programme (2001) Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2000. Commun Dis Intell 25: 274-277.
77. Tomasz A (1997) Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 24(Suppl 1): S85-S88.
78. Tufts Center for the Study of Drug Development (2003) Post-approval R&D raises total drug development costs to $897 million. Impact Report, Vol 5, no. 3.
79. van den Ent F & Löwe J (2000) Crystal structure of the cell division protein FtsA from Thermotoga maritima. EMBO J 19: 5300-5307.
80. Varaldo PE (2002) Antimicrobial resistance and susceptibility testing: an evergreen topic. J Antimicrob Chemother 50: 1-4.
81. Vicente M, Rico AI, Martínez-Arteaga R & Mingorance J (2006) Septum enlightenment: the assembly of the bacterial division proteins. J Bacteriol 188: 19-27.
82. Weber JT (2005) Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 41(Suppl 4): S269-S272.
83. World Health Organization (1996) The World Health Report 1996 - Fighting Disease, Fostering Development. World Health Organization, Geneva.
84. World Health Organization (2000) Anti-tuberculosis Drug Resistance in the World. Report no. 2: Prevalence and Trends. WHO/CDS/TB/2000/.278 The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. World Health Organization, Geneva.
85. Zaman GJ, Michiels PJ & van Boeckel CA (2003) Targeting RNA: new opportunities to address drugless targets. Drug Discov Today 8: 297-306.
86. Zielenkiewicz U & Ceglowski P (2005) The toxin-antitoxin system of the streptococcal plasmid pSM19035. J Bacteriol 187: 6094-6105.